AMARYL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Amaryl, and what generic alternatives are available?
Amaryl is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in AMARYL is glimepiride. There are sixteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the glimepiride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Amaryl
A generic version of AMARYL was approved as glimepiride by CHARTWELL MOLECULAR on October 6th, 2005.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AMARYL?
- What are the global sales for AMARYL?
- What is Average Wholesale Price for AMARYL?
Summary for AMARYL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 154 |
Clinical Trials: | 69 |
Patent Applications: | 4,359 |
Drug Prices: | Drug price information for AMARYL |
What excipients (inactive ingredients) are in AMARYL? | AMARYL excipients list |
DailyMed Link: | AMARYL at DailyMed |
Recent Clinical Trials for AMARYL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Damanhour University | N/A |
PT Harsen Laboratories | N/A |
PT Pharma Metric Labs | N/A |
US Patents and Regulatory Information for AMARYL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | AMARYL | glimepiride | TABLET;ORAL | 020496-001 | Nov 30, 1995 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Sanofi Aventis Us | AMARYL | glimepiride | TABLET;ORAL | 020496-002 | Nov 30, 1995 | AB | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Sanofi Aventis Us | AMARYL | glimepiride | TABLET;ORAL | 020496-003 | Nov 30, 1995 | AB | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AMARYL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | AMARYL | glimepiride | TABLET;ORAL | 020496-001 | Nov 30, 1995 | ⤷ Subscribe | ⤷ Subscribe |
Sanofi Aventis Us | AMARYL | glimepiride | TABLET;ORAL | 020496-003 | Nov 30, 1995 | ⤷ Subscribe | ⤷ Subscribe |
Sanofi Aventis Us | AMARYL | glimepiride | TABLET;ORAL | 020496-002 | Nov 30, 1995 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for AMARYL
See the table below for patents covering AMARYL around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 0031058 | SULFONYL UREAS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | ⤷ Subscribe |
Spain | 498228 | ⤷ Subscribe | |
Denmark | 540280 | ⤷ Subscribe | |
Mexico | 8254 | PROCEDIMIENTO PARA LA ELABORACION DE SULFONIL UREAS Y PRODUCTO RESULTANTE | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for AMARYL
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1174135 | SPC/GB10/011 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: THE COMBINATION OF PIOGLITAZONE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY THE HYDROCHLORIDE SALT, AND GLIMEPIRIDE.; REGISTERED: UK EU/1/06/366/001 20070108; UK EU/1/06/366/002 20070108; UK EU/1/06/366/003 20070108; UK EU/1/06/366/004 20070108; UK EU/1/06/366/005 20070108; UK EU/1/06/366/006 20070108; UK EU/1/06/366/019 20070108; UK EU/1/06/366/020 20070108; UK EU/1/06/366/021 20070108; UK EU/1/06/366/022 20070108; UK EU/1/06/366/013 20070108; UK EU/1/06/366/014 20070108; UK EU/1/06/366/015 20070108; UK EU/1/06/366/016 20070108; UK EU/1/06/366/017 20070108; UK EU/1/06/366/018 20070108; UK EU/1/06/366/007 20070108; UK EU/1/06/366/008 20070108; UK EU |
0031058 | 98C0008 | Belgium | ⤷ Subscribe | PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203 |
0031058 | SPC/GB97/012 | United Kingdom | ⤷ Subscribe | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
AMARYL Market Analysis and Financial Projection Experimental
More… ↓